Insulin: Evidence, Mechanism, Dosing & Legal Status

Insulin is the prototypical therapeutic peptide hormone and the anchor of the claim that "peptides are real medicine": a 51-amino-acid, two-chain protein that became, as recombinant Humulin in 1982, the first FDA-approved drug of any kind made by recombinant-DNA technology.1819 This monograph separates what is proven — and it is a great deal — from the one place where insulin is hyped and lethal.

This article is informational and editorial content for research and educational purposes only. It is not medical advice, not a protocol to follow, and not a sourcing guide. Insulin is a high-alert medication: dosing errors and non-prescribed use can cause fatal hypoglycemia. Dosing figures are reported strictly as seen in clinical guidelines and the published literature for completeness. Consult a licensed clinician for any diabetes or metabolic care.

What is insulin and how does it work?

Insulin is a peptide hormone of 51 amino acids arranged as two chains — an A-chain (21 residues) and a B-chain (30 residues) — held together by two interchain disulfide bonds, with a third intrachain disulfide in the A-chain. Secreted by pancreatic beta-cells, it is a highly potent anabolic hormone central to glucose, lipid and protein metabolism.2 Therapeutic insulin is now produced by recombinant DNA in E. coli or yeast rather than extracted from pig or cow pancreas as it was historically.4

Insulin acts on the insulin receptor (IR), a receptor tyrosine kinase that is structurally unusual — a preformed, covalently linked alpha-2-beta-2 tetramer rather than a single-chain RTK.2 Insulin binding to the alpha-subunits induces a large conformational change that activates the beta-subunit kinase, triggering trans-autophosphorylation and recruitment of insulin-receptor-substrate (IRS) proteins; phosphorylated IRS then activates two principal cascades — the PI3K-AKT pathway (mediating GLUT4-driven glucose uptake, glycogen synthesis, lipogenesis and protein synthesis via mTOR) and the RAS-MAPK pathway (mediating growth and mitogenic signaling).13 The net physiologic effect is suppression of hepatic glucose output, stimulation of peripheral glucose uptake, and a broad anabolic program — the same anabolic biology misused for muscle gain.

Because insulin is a peptide, it is destroyed by gastrointestinal peptidases and first-pass hepatic metabolism, so it is not orally bioavailable — the central reason injection has remained the mainstay and why "oral insulin" remains an unsolved delivery problem.26 The therapeutic analog landscape engineers the subcutaneous absorption profile: rapid-acting analogs (lispro, aspart, glulisine) dissociate quickly from hexamers to monomers for an earlier peak and better prandial coverage with less late hypoglycemia, while long-acting basal analogs (glargine, detemir, degludec) give a flatter, roughly 24-hour peakless profile. In a randomized double-blind glucose-clamp crossover study, glargine held plasma glucose stable out to 24 hours whereas detemir waned after about 16 hours.7 Inhaled insulin (Afrezza) sidesteps GI degradation entirely, with the fastest action of any approved insulin.2324

What is the evidence by indication?

Unlike most peptides in this encyclopedia, insulin's evidence is overwhelmingly human and overwhelmingly strong. The American Diabetes Association Standards of Care codify its role across every major indication.9

In type 1 diabetes insulin is absolutely required — there is no alternative to exogenous insulin for absolute insulin deficiency, and basal-bolus analog regimens are the guideline-recommended standard.9 In type 2 diabetes, basal insulin (often added to metformin, an SGLT2 inhibitor or a GLP-1 receptor agonist) reliably lowers HbA1c when non-insulin therapy is insufficient, and analogs reduce nocturnal and overall hypoglycemia versus NPH while achieving similar A1c.5 The large ORIGIN RCT showed glargine was cardiovascular-neutral and did not raise overall cancer incidence versus standard care.20 Head-to-head trials and systematic reviews further establish that rapid analogs lispro and aspart are clinically equivalent, and that the interchangeable biosimilar Semglee matches reference Lantus on PK/PD, efficacy, safety and immunogenicity.627 For diabetic ketoacidosis and inpatient hyperglycemia, IV regular insulin is the established treatment, codified in guidance rather than tested against placebo because withholding insulin would be unethical.9

What doses appear in the literature?

Reported strictly as information from clinical guidelines, not a protocol. Insulin is a high-alert medication; dosing must be individualized and clinician-supervised. For type 1 diabetes the literature figure in metabolically stable adults is roughly 0.5 U/kg/day total, split about 50% basal and 50% prandial, with lower weight-based doses (0.2-0.6 U/kg/day) during the honeymoon period, in children, or with residual beta-cell function.9 For type 2 diabetes, basal initiation is commonly 0.1-0.2 U/kg/day (or a flat 10 U/day), titrated to fasting glucose while continuing metformin, SGLT2 inhibitors or GLP-1 receptor agonists; the 2025 ADA update replaced the old ">0.5 U/kg/day" over-basalization threshold with functional criteria.10 Routes include subcutaneous (vial, pen or pump) for routine care, intravenous regular insulin for crises, and inhaled Afrezza as a mealtime option carrying a boxed warning.23 Although manufacturers caution against mixing glargine with rapid analogs, clamp studies have not shown deleterious effects on glucose excursions when mixed.8

How safe is insulin, and what is the misuse danger?

Insulin's defining hazard is hypoglycemia; severe untreated hypoglycemia causes seizures, coma and death, and analogs reduce but do not eliminate the risk.95 Other adverse effects include weight gain, injection-site lipohypertrophy, hypokalemia (insulin drives potassium intracellularly, relevant at high or IV doses and in DKA), and rare hypersensitivity. A theoretical mitogenicity concern — because the IR is homologous to the IGF-1 receptor, glargine shows greater in-vitro IGF-1R affinity than human insulin — has been largely resolved reassuringly: glargine is rapidly metabolized subcutaneously to metabolites with reduced IGF-1R binding, and the ORIGIN RCT plus meta-analyses show no clinically meaningful increase in overall cancer risk.202122 Insulin is also the established agent for hyperglycemia in pregnancy because it does not cross the placenta in meaningful amounts.9

The critical safety caveat for a peptide audience is non-medical misuse. Insulin is described in the sports-medicine literature as one of the most dangerous performance-enhancing drugs precisely because the margin between an "anabolic" dose and a lethal one is narrow and hypoglycemia onsets rapidly.12 A published case describes a 30-year-old male bodybuilder in coma from severe, treatment-refractory hypoglycemia requiring iterative glucose infusions, ultimately traced to cryptic (concealed) insulin injections — the authors warn emergency physicians to suspect exogenous insulin in athletes with depressed consciousness and refractory hypoglycemia.11 Survey data describe a predominantly young, male recreational-exerciser population frequently co-using anabolic steroids.1314 There is no safe non-prescribed use.

What is the FDA and WADA status in 2026?

Insulin is fully FDA-approved and foundational. Recombinant Humulin was approved on October 28, 1982, the first recombinant-DNA medicine of any kind (developed by Genentech and City of Hope, licensed to Eli Lilly).1819 Numerous analogs and inhaled Afrezza (2014) are approved.25 In March 2020 the FDA transitioned insulin and other proteins from the drug (NDA) pathway to the biologics (351) pathway under the BPCIA, enabling biosimilars and interchangeables; Semglee (insulin glargine-yfgn) became the first interchangeable biosimilar in the U.S. on July 28, 2021, permitting pharmacy-level substitution for Lantus.27 Insulin is a prescription biologic but not a DEA-scheduled controlled substance — though it remains a high-alert medication, not a research chemical.

For athletes the picture is unambiguous. Under WADA's 2026 Prohibited List, in force January 1, 2026, insulin is prohibited at all times for non-diabetic athletes, listed under S4.4.2 "Insulins and Insulin-Mimetics" and as a peptide hormone under S2, with use permitted only via a valid Therapeutic Use Exemption for diabetes. The official list is published at wada-ama.org, and the WADA S4 category detail is catalogued by reference sources.151617

Bottom line. Insulin is both the proof-of-concept that peptides are medicine and the cautionary archetype that a real, potent peptide hormone is not a supplement to be self-administered. Proven, Grade-A and life-saving in diabetes; lethal and unproven as a bodybuilding "anabolic." Regulatory and guideline facts here are current as of June 2026 and should be re-verified against the latest ADA Standards of Care and WADA Prohibited List.